Inibio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 135

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Latest Deal Amount
  • $27.6M

  • Investors
  • 3

Inibio General Information

Description

Operator of a biomedical company intended to make botulinum toxin. The company specializes in medical aesthetics and develops Botox based on plant-derived ingredients, providing customers with Botox that offers proven stability and efficacy, enabling healthcare providers and global partners to access high-quality, compliant products for skin health and therapeutic applications.

Contact Information

Website
www.inibio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 506 Songnae-daero
  • Ojeong-gu
  • Bucheon, Gyeonggi 14445
  • South Korea
+82
Primary Industry
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 506 Songnae-daero
  • Ojeong-gu
  • Bucheon, Gyeonggi 14445
  • South Korea
+82

Inibio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inibio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 12-Feb-2025 $27.6M Completed Generating Revenue
4. Later Stage VC 01-Jan-2025 Completed Generating Revenue
3. Later Stage VC (Series B) 07-Feb-2022 Completed Generating Revenue
2. Early Stage VC (Series A) 20-Apr-2021 Completed Generating Revenue
1. Seed Round 18-Dec-2018 Completed Generating Revenue
To view Inibio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Inibio Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

Inibio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4563924-A1 Decompression drying device and decompression drying method using same Pending 27-Jul-2022
EP-4563924-A4 Decompression drying device and decompression drying method using same Pending 27-Jul-2022
US-20260036368-A1 Decompression drying device and decompression drying method using same Pending 27-Jul-2022
JP-2024538830-A Drying process for botulinum toxin preparations Active 11-Nov-2021
AU-2022388245-A1 Drying process of botulinum toxin formulation Pending 11-Nov-2021 C12N9/52
To view Inibio’s complete patent history, request access »

Inibio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inibio Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
GC Biopharma Corporation Minority
J&P Private Equity PE/Buyout Minority
Premier Partners PE/Buyout Minority
To view Inibio’s complete investors history, request access »

Ready to get started?

Request a free trial

Inibio FAQs

  • When was Inibio founded?

    Inibio was founded in 2017.

  • Where is Inibio headquartered?

    Inibio is headquartered in Bucheon, South Korea.

  • What is the size of Inibio?

    Inibio has 135 total employees.

  • What industry is Inibio in?

    Inibio’s primary industry is Biotechnology.

  • Is Inibio a private or public company?

    Inibio is a Private company.

  • What is the current valuation of Inibio?

    The current valuation of Inibio is .

  • What is Inibio’s current revenue?

    The current revenue for Inibio is .

  • Who are Inibio’s investors?

    GC Biopharma, J&P Private Equity, and Premier Partners have invested in Inibio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process